Biomarkers enhance the long-term predictive ability of the KAMIR risk score in Chinese patients with ST-elevation myocardial infarction

Jian-Jun Wang1, Yan Fan2, Yan Zhu2, Jian-Dong Zhang1, Su-Mei Zhang3, Zhao-Fei Wan4, Hong-Ling Su2, Na Jiang2

1Department of Orthopaedics, The First People’s Hospital of Lanzhou, Lanzhou, Gansu 730050, China; 2Department of Cardiovascular Medicine, Gansu Provincial Hospital, Lanzhou, Gansu 730000, China; 3Department of Nursing, Xi’an Medical University, Xi’an, Shaanxi 710021, China; 4Department of Cardiovascular Medicine, the First Affiliated Hospital of Xi’an Jiaotong University School of Medicine, Xi’an, Shaanxi 710061, China.

Abstract
Background: The Global Registry of Acute Coronary Events (GRACE) score is recommended by current ST-elevation myocardial infarction (STEMI) guidelines. But it has inherent defects. The present study aimed to investigate the more compatible risk stratification for Chinese patients with STEMI and to determine whether the addition of biomarkers to the Korea Acute Myocardial Infarction Registry (KAMIR) score could enhance its predictive value for long-term outcomes.

Methods: A total of 1093 consecutive STEMI patients were included and followed up 48.2months. Homocysteine, hypersensitive C-reactive protein (hs-CRP), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were detected. The KAMIR score and the GRACE score were calculated. The performance between the KAMIR and the GRACE was compared. The predictive power of the KAMIR alone and combined with biomarkers were assessed by the receiver-operating characteristic (ROC) curve.

Results: The KAMIR demonstrated a better risk stratification and predictive ability than the GRACE (death: AUC=0.802 vs. 0.721, P<0.001; major adverse cardiovascular events (MACE): AUC=0.683 vs. 0.656, P<0.001). It showed that the biomarkers could independently predict death [homocysteine: HR=1.019 (1.015–1.024), P<0.001; hs-CRP: HR=1.052 (1.000–1.104), P=0.018; NT-pro BNP: HR=1.142 (1.004–1.280), P=0.021] and MACE [homocysteine: HR=1.019 (1.015–1.024), P<0.001; hs-CRP: HR=1.012 (1.003–1.021), P=0.020; NT-pro BNP: HR=1.136 (1.104–1.168), P=0.006]. When they were used in combination with the KAMIR, the area under the ROC curve (AUC) significantly increased for death [homocysteine: AUC=0.802 vs. 0.890, Z=5.982, P<0.001; hs-CRP: AUC=0.802 vs. 0.871, Z=3.721, P<0.001; NT-pro BNP: AUC=0.802 vs. 0.871, Z=2.187, P=0.047; homocysteine, hs-CRP and NT-pro BNP: AUC=0.802 vs. 0.940, Z=6.177, P<0.001] and MACE [homocysteine: AUC=0.683 vs. 0.771, Z=6.818, P<0.001; hs-CRP: AUC=0.683 vs. 0.712, Z=2.022, P=0.031; NT-pro BNP: AUC=0.683 vs. 0.720, Z=2.974, P=0.003; homocysteine, hs-CRP and NT-pro BNP: AUC=0.683 vs. 0.789, Z=6.900, P<0.001].

Conclusion: The KAMIR is better than the GRACE in risk stratification and prognosis prediction in Chinese STEMI patients. A combination of above-mentioned biomarkers can develop a more predominant prediction for long-term outcomes.

Keywords: ST-elevation myocardial infarction; the Korea Acute Myocardial Infarction Registry risk score; the Global Registry of Acute Coronary Events risk score; homocysteine; hypersensitive C-reactive protein; N-terminal pro-B-type natriuretic peptide

Introduction
Patients with ST-elevation myocardial infarction (STEMI) face various risks of adverse cardiovascular events.[1] Risk stratification, therefore, is a cornerstone in the modern management and treatment of STEMI.[2,3] Several models have been developed to perform risk stratification, such as the Thrombolysis in Myocardial Infarction (TIMI), Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT), and the Global Registry of Acute Coronary Events (GRACE).[4] However, these models have inherent defects.[5,6] Even the GRACE risk scoring system,[6] which is recommended by current STEMI management guidelines,[2,3] is developed for short-term prognosis and its calculation is tedious. Furthermore, the GRACE risk scoring system was validated on the basis of early data. Patients and procedural characteristics in STEMI have been changing.[7] Thus current clinical treatments may no longer fit the GRACE score. Moreover, the GRACE risk scoring system...
was developed based on patients in Europe and America, whose characteristics may differ from the Asians.

Recently, a new risk prediction model, the Korea Acute Myocardial Infarction Registry (KAMIR) score, is developed to assess risks of clinical outcomes in acute myocardial infarction (AMI). This model has advantages in simplicity and accuracy simultaneously for both short- and long-term risk assessment, and has the potential to be a powerful predictive tool for prognosis of AMI. Research has already shown that the KAMIR score does a better job than the GRACE score in predicting the clinical outcomes in AMI patients in Korea. It will be valuable to see if this advantage also exists in patients in other areas. Up to now, no studies have been found to compare the effects of the KAMIR score and the GRACE score in Chinese STEMI patients.

Extensive research has been conducted to evaluate the effectiveness of risk prediction models and to explore how to improve the effectiveness. It is already confirmed that biomarkers can strengthen the predictive capability of the models. For example, homocysteine, neutrophil count, mean platelet volume, cystatin C, hypersensitive C-reactive protein (hs-CRP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15), and red blood cell fatty acid have been reported to be able to reinforce risk assessment beyond the GRACE score. This suggests room and possibility for improvement in the KAMIR scoring system. The biomarkers, being considered in the system, are limited to creatinine and glucose. However, studies have found that homocysteine, hs-CRP, and NT-pro BNP have a vigorous response following AMI and their plasma levels are related to mortality. These biomarkers help to reveal the pathological process of AMI in terms of metabolism, inflammation, and neuroendocrine. In spite of the important values of these biomarkers in AMI, they are not included in the KAMIR score, and there are by far no reports on whether they could enhance the predictive ability of the KAMIR score. In particular, no studies have been conducted to evaluate the potential influences of these biomarkers on the KAMIR score in STEMI. In the present study, we compared the predictive ability of the GRACE score and the KAMIR score in Chinese STEMI patients and investigated whether combination of the above-mentioned 3 biomarkers with the KAMIR score could better predict the long-term clinical outcomes in the Chinese patients. The aim of our analyses was to identify a risk prediction model that fits Chinese STEMI patients better.

Methods

Ethical approval

The study was approved by the Ethics Committees of Gansu Provincial Hospital and the First Affiliated Hospital of Xi’an Jiaotong University School of Medicine. It was performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all the patients.

Study population

From January 2010 to December 2012, 1093 consecutive patients upon a confirmed diagnosis of STEMI were admitted to the Department of Cardiology in the two hospitals with facilities for primary percutaneous coronary intervention (PCI) and on-site cardiac surgery in China. The diagnostic criteria followed the American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines of STEMI. Patients with malignant tumors or severe liver or kidney dysfunction were excluded. These patients have all received PCI treatment.

Biomarker detection

Blood samples were collected from the patients, and then the serum was obtained by centrifugation at 4°C and stored in aliquots at –80°C. All laboratory parameters, including triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDLC), Low-density lipoprotein cholesterol (LDLC), plasma glucose, creatinine, uric acid, CysC, creatine kinase (CK), creatine kinase-myocardial band (CK-MB), cardiac troponin, homocysteine, hs-CRP, and NT-pro BNP, were detected in the Biochemical Departments of the two hospitals where the same laboratory standards were followed.

Echocardiography

Comprehensive echocardiographic analysis of cardiac structure and function was performed by a single experienced physician following the echocardiography guidelines to achieve measurement stability. All measurements were averaged over 3 cardiac cycles. The indexes of left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic dimension (LVESD), left ventricular end-diastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) were normalized according to body surface area. Left ventricular mass was calculated using the recommended formula of the American Society of Echocardiography and the left ventricular mass index was also normalized. Regional wall motion was assessed using a left ventricular 16-segment model and a 4-point grading scale. The wall-motion score index was calculated as the sum of the score of each segment divided by the number of segments scored. A higher index corresponds to weaker wall motion.

Coronary angiography

Coronary angiography was performed according to the standard method. The images were analyzed by a single specialist. Coronary single-vessel disease was defined as >50% stenosis in a major coronary artery (eg, left anterior descending coronary artery, left circumflex coronary artery, or right coronary artery) and/or their main branches. Multiple-vessel disease was defined as >50% stenosis in more than 1 major coronary artery. The Gensini score was calculated to assess the severity of stenosis. The higher the score, the more severe the coronary artery lesion would be.
**Baseline data**

Baseline data including demographic information, clinical data, and medication usage were collected using a standard case report form. The KAMIR risk score was calculated as described in the literature.[8] Six independent variables related to cardiovascular events, namely age, Killip class, serum creatinine, no in-hospital PCI, left ventricular ejection fraction (LVEF), and admission glucose, were involved via a multivariable Cox proportional hazard regression analysis. The GRACE risk score was also calculated as described previously.[8] Values of variables, including age, heart rate, systolic blood pressure, serum creatinine level, history of congestive heart failure, in-hospital PCI, in-hospital coronary artery bypass graft surgery (CABG), previous MI, ST-segment depression, and elevated cardiac markers, were entered into the GRACE risk calculator to obtain the score.

**Follow-up**

Patient follow-up was performed by a group of medical staff. All patients were followed up by telephone calls or interviews to track the occurrence of cardiovascular events and medication adherence. The major adverse cardiovascular events (MACE) included all-cause death, rehospitalization due to heart failure or angina symptoms, recurrent nonfatal MI, repeated coronary revascularization, and stroke.

**Statistical analysis**

Continuous variables are presented as mean ± standard deviation (SD) or median (inter-quartile range). Categorical variables are presented as frequency (percentage). The data were checked for normality using the Kolmogorov-Smirnov test. Independent-samples t test or Mann-Whitney U test was used to examine the differences between continuous variables, as appropriate. The Pearson χ² test or Fisher exact test was used to determine the differences between categorical variables, as appropriate. Univariate and multivariate Cox proportional hazard regression analysis was performed to identify predictors for adverse clinical outcomes. The outcomes were further evaluated by the Kaplan-Meier curve, and intergroup comparisons were conducted with the log-rank test. The potential correlation between the aforementioned 3 biomarkers (homocysteine, hs-CRP, and NT-pro BNP), the KAMIR score, and the GRACE score were associated with higher risks of all-cause death and MACE. Moreover, the homocysteine, hs-CRP, and NT-pro BNP levels, the KAMIR score, and the GRACE score were significantly higher in patients with MACE.

**Analysis of factors correlated with clinical outcomes**

Cox proportional hazard regression analyses were performed to identify the predictive factors for clinical outcomes. Tables 3 and 4 summarize the results of univariate and multivariate Cox proportional hazard regression analyses for all-cause death or MACE in these patients. Univariate analysis showed that the aforementioned 3 biomarkers (homocysteine, hs-CRP, and NT-pro BNP), the KAMIR score, and the GRACE risk score were associated with higher risks of all-cause death and MACE. After adjusted for potential confounding factors, such as age, gender, body mass index, heart rate, blood pressure, smoking, hypertension, dyslipidemia, diabetes, and Killip classification, homocysteine, hs-CRP, NT-pro BNP, the KAMIR risk score, and the GRACE risk score remained to be significant predictors for all-cause death [homocysteine: HR = 1.019 (1.015–1.024), P < 0.001; hs-CRP: HR = 1.052 (1.000–1.104), P = 0.018; NT-pro BNP: HR = 1.142 (1.004–1.280), P = 0.021; KAMIR score: HR = 1.142 (1.004–1.280), P = 0.021; GRACE score: HR = 1.015 (1.005–1.025), P = 0.003] and MACE [homocysteine: HR = 1.019 (1.015–1.024), P < 0.001; hs-CRP: HR = 1.012 (1.003–1.021), P = 0.020; NT-pro BNP: HR = 1.136 (1.104–1.168), P = 0.006; KAMIR score: HR = 1.566 (1.421–1.726), P < 0.001; GRACE score: HR = 1.010 (1.007–1.012), P < 0.001].
Table 1: Baseline characteristics of patients with ST-elevation myocardial infarction

| Clinical characteristics | Results |
|--------------------------|---------|
| Male gender, n (%)       | 929 (85) |
| Age (years)              | 58.45±11.45 |
| Body mass index (kg/m²)  | 23.94±2.78 |
| Heart rate (beats/min)   | 76.06±15.48 |
| Systolic blood pressure (mmHg) | 121.85±20.46 |
| Diastolic blood pressure (mmHg) | 76.92±13.24 |
| Smoking, n (%)           | 771 (70.5) |
| Hypertension, n (%)      | 477 (43.6) |
| Dyslipidemia, n (%)      | 192 (17.6) |
| Diabetes, n (%)          | 157 (14.4) |
| History of myocardial infarction, n (%) | 69 (6.3) |
| History of revascularization, n (%) | 29 (2.7) |
| History of cerebrovascular disease, n (%) | 80 (7.3) |
| Family history of coronary heart disease, n (%) | 101 (9.2) |
| Anterior wall infarct, n (%) | 626 (57.3) |
| Killip classification, n (%) |  |
| Class I                  | 701 (64.1) |
| Class II                 | 296 (27.1) |
| Class III                | 57 (5.2) |
| Class IV                 | 39 (3.6) |
| Laboratory examinations  |         |
| Triglycerides (mmol/L)   | 1.63±0.92 |
| Total cholesterol (mmol/L) | 4.09±1.21 |
| Low-density lipoprotein cholesterol (mmol/L) | 2.38±0.82 |
| Blood glucose (mmol/L)   | 7.82±4.00 |
| Uric acid (μmol/L)       | 305.69±91.72 |
| Cystatin C (mg/L)        | 1.07±0.97 |
| Homocysteine (μmol/L)    | 21.45±15.09 |
| Hypersensitive C-reactive protein (mg/L), median (IQR) | 9.28 (3.80, 25.80) |
| N-terminal pro-B-type natriuretic peptide (pg/mL), median (IQR) | 877.20 (360.95, 1751.0) |
| Creatine phosphokinase-myocardial band (U/L), median (IQR) | 63.99 (15.03, 191.20) |
| eGFR (mL·min⁻¹·1.73m²)  | 113.55±46.20 |
| Ultrasound cardiogram parameters |   |
| Left ventricular end-diastolic dimension index (cm/m²) | 3.02±0.41 |
| Left ventricular end-systolic dimension index (cm/m²) | 2.15±0.45 |
| Left ventricular end-diastolic volume index (mL/m²) | 58.66±14.08 |
| Left ventricular end-systolic volume index (mL/m²) | 30.82±11.75 |
| Left ventricular mass index (g/m²) | 90.63±23.28 |
| Left ventricular fraction shortening (%) | 29.33±7.79 |
| Left ventricular ejection fraction (%) | 53.42±11.09 |
| Wall motion score index | 1.27±0.19 |
| Coronary angiography characteristics |   |
| Multiple-vessel disease, n (%) | 633 (57.9) |
| Gensini score            | 69.76±39.86 |
| Risk score               |         |
| KAMIR risk score         | 1.87±1.21 |
| GRACE risk score 1       | 98.08±28.83 |
| GRACE risk score 2       | 128.25±44.08 |
| Medicine, n (%)          |         |
| Aspirin                  | 1043 (95.4) |
| Clopidogrel/Ticagrelor   | 1087 (99.5) |
| Statin                   | 1040 (95.2) |
| Angiotensin-converting enzyme inhibitor/Angiotensin receptor blocker | 1010 (92.4) |
| β-Blocker                | 999 (91.4) |
| Platelet glycoprotein IIbIIIa receptor antagonist | 773 (70.7) |

eGFR: estimated glomerular filtration rate; KAMIR risk score: the Korea Acute Myocardial Infarction Registry risk score; GRACE risk score: the Global Registry of Acute Coronary Events risk score (GRACE risk score 1: the algorithms of probability for death at admission; GRACE risk score 2: the algorithms of probability for death or myocardial infarction at admission). eGFR is calculated according to the MDRD formula: eGFR (mL·min⁻¹·1.73m² of body surface area) = 186 × (SCr⁻1.154 × (Age)⁻0.203 (× 0.742 for females). SCr is reported in mg/dL.
Table 2: Baseline data of patients with or without MACE

| Items                                      | With MACE (n=278) | Without MACE (n=815) | Statistics | P value |
|--------------------------------------------|-------------------|----------------------|------------|---------|
| Clinical characteristics                   |                   |                      |            |         |
| Male gender                                | 220 (79.1)        | 709 (87.0)           | 10.035†    | 0.002   |
| Age (years)                                | 62.94±11.56       | 56.91±11.00          | 7.596*     | <0.001  |
| Body mass index (kg/m²)                    | 23.93±2.72        | 23.95±2.80           | -0.117*    | 0.907   |
| Heart rate (beats/min)                     | 80.28±19.10       | 74.62±13.76          | 4.562*     | <0.001  |
| Systolic blood pressure (mmHg)             | 120.76±22.22      | 122.22±19.83         | -0.973*    | 0.331   |
| Diastolic blood pressure (mmHg)            | 75.73±14.32       | 77.32±12.84          | -1.642*    | 0.101   |
| Smoking                                    | 201 (72.3)        | 530 (65.0)           | 5.293†     | 0.021   |
| Hypertension                               | 136 (48.9)        | 341 (41.8)           | 4.225γ     | 0.040   |
| Dyslipidemia                               | 59 (21.2)         | 133 (16.3)           | 3.443γ     | 0.064   |
| Diabetes                                   | 36 (12.9)         | 121 (14.8)           | 0.606γ     | 0.436   |
| History of myocardial infarction           | 22 (7.9)          | 47 (5.8)             | 1.615γ     | 0.204   |
| History of revascularization               | 7 (2.5)           | 22 (2.7)             | 0.026γ     | 0.871   |
| History of cerebrovascular disease         | 25 (9.0)          | 55 (6.7)             | 1.539γ     | 0.215   |
| Family history of coronary heart disease   | 29 (10.4)         | 47 (5.8)             | 1.239γ     | 0.020   |
| Anterior wall infarct                      | 166 (59.7)        | 460 (56.4)           | 0.906γ     | 0.341   |
| Killip classification                      | 82.274†           | <0.001               |            |         |
| Class I                                    | 140 (50.4)        | 561 (68.8)           |            |         |
| Class II                                   | 78 (28.1)         | 218 (26.7)           |            |         |
| Class III                                  | 33 (11.9)         | 24 (2.9)             |            |         |
| Class IV                                   | 27 (9.7)          | 12 (1.5)             |            |         |
| Laboratory examinations                    |                   |                      |            |         |
| Triglycerides (mmol/L)                     | 1.58±0.95         | 1.64±0.90            | -1.043†    | 0.297   |
| Total cholesterol (mmol/L)                 | 4.14±1.48         | 4.07±1.11            | 0.807†     | 0.420   |
| Low-density lipoprotein cholesterol (mmol/L)| 2.43±0.81       | 2.36±0.82            | 1.262     | 0.208   |
| Blood glucose (mmol/L)                     | 8.32±4.88         | 7.65±3.63            | 2.107γ     | 0.036   |
| Uric acid (μmol/L)                         | 324.50±109.46     | 299.28±83.95         | 3.506γ     | 0.001   |
| Cystatin C (mg/L)                          | 1.11±0.76         | 1.06±1.03            | 0.821†     | 0.412   |
| Homocysteine (μmol/L)                      | 29.82±22.38       | 18.59±10.14          | 8.086γ     | <0.001  |
| Hypersensitive C-reactive protein (mg/L), median | 625.15         | 520.34               | 5.368γ     | <0.001  |
| N-terminal pro-B-type natriuretic peptide (pg/mL), median | 697.54         | 495.65               | 6.671γ     | <0.001  |
| Creatine phosphokinase-myocardial band (U/L), median | 541.28          | 548.95               | -0.375γ    | 0.726   |
| eGFR (mL·min⁻¹·1.73m⁻²)                    | 116.53±66.15      | 112.53±37.02         | 0.957γ     | 0.339   |
| Ultrasound cardiogram parameters           |                   |                      |            |         |
| Left ventricular end-diastolic dimension index (cm²/m²) | 3.09±0.44       | 3.00±0.40            | 3.141γ     | 0.002   |
| Left ventricular end-systolic dimension index (cm²/m²) | 2.24±0.49       | 2.12±0.43            | 3.842γ     | <0.001  |
| Left ventricular end-diastolic volume index (mL/m²) | 60.36±14.66     | 58.07±13.84          | 2.346γ     | 0.019   |
| Left ventricular end-systolic volume index (mL/m²) | 33.07±12.44     | 30.06±11.41          | 3.711γ     | <0.001  |
| Left ventricular mass index (g/m²)         | 95.02±24.80       | 89.13±22.56          | 3.665γ     | <0.001  |
| Left ventricular fraction shortening (%)   | 27.75±7.96        | 29.87±7.66           | -4.106γ    | <0.001  |
| Left ventricular ejection fraction (%)      | 51.08±11.37       | 54.22±10.89          | -3.951γ    | <0.001  |
| Wall motion score index                    | 1.29±0.21         | 1.27±0.19            | 1.813γ     | 0.070   |
| Coronary angiography characteristics       |                   |                      |            |         |
| Multiple-vessel disease                    | 157 (56.5)        | 469 (57.5)           | 4.785γ     | 0.323   |
| Gensini score                              | 82.00±42.12       | 66.13±38.45          | 5.504γ     | <0.001  |
| Risk score                                 |                   |                      |            |         |
| KAMIR risk score                           | 2.61±1.56         | 1.62±0.93            | 9.995γ     | <0.001  |
| GRACE risk score 1                         | 113.32±31.95      | 92.88±25.71          | 9.653γ     | <0.001  |
| GRACE risk score 2                         | 147.04±46.06      | 121.84±41.51         | 8.070γ     | <0.001  |

* t value, † x² value, eGFR: estimated glomerular filtration rate; KAMIR risk score: the Korea Acute Myocardial Infarction Registry risk score; GRACE risk score: the Global Registry of Acute Coronary Events risk score; MACE: major adverse cardiovascular events.

**Performance of the KAMIR risk score precedes the GRACE risk score**

The accuracy of predicting all-cause death by the KAMIR score was AUC 0.802 (95% CI: 0.753–0.852) and that by the GRACE score was 0.721 (95% CI: 0.672–0.770) (P < 0.001). For MACE, the accuracy was AUC 0.683 (95% CI: 0.644–0.723) by the KAMIR score and 0.656 (95% CI: 0.618–0.693) by the GRACE score (P < 0.001). Figure 1 demonstrates the greater power of the KAMIR score, as
Table 3: Cox proportional hazard regression analyses for all-cause death

| Items                                      | Univariate analysis | Multivariate analysis |
|--------------------------------------------|---------------------|-----------------------|
|                                            | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| Age                                        | 1.085 (1.065–1.107) | <0.001                | 1.070 (1.048–1.092) | <0.001                |
| Female gender                              | 2.443 (1.611–3.705) | <0.001                | 1.835 (1.147–2.936) | 0.011                |
| Heart rate                                 | 1.028 (1.019–1.037) | <0.001                | 1.018 (1.008–1.028) | <0.001                |
| Diastolic blood pressure                   | 0.982 (0.968–0.997) | 0.020                 |                      |                      |
| Killip classification                      | 2.178 (1.826–2.597) | <0.001                |                      |                      |
| eGFR                                       | 1.004 (1.001–1.007) | 0.003                 |                      |                      |
| Blood glucose                              | 1.060 (1.029–1.091) | <0.001                |                      |                      |
| Uric acid                                  | 1.004 (1.002–1.006) | <0.001                |                      |                      |
| Homocysteine                               | 1.025 (1.021–1.029) | <0.001                | 1.019 (1.015–1.024) | <0.001                |
| Hypersensitive C-reactive protein          | 1.070 (1.005–1.135) | <0.001                | 1.052 (1.000–1.104) | 0.018                |
| N-terminal pro-B-type natriuretic peptide  | 1.181 (1.024–1.338) | <0.001                | 1.142 (1.004–1.280) | 0.021                |
| Left ventricular end-diastolic dimension index | 1.885 (1.271–2.794) | 0.002                |                      |                      |
| Left ventricular end-diastolic volume index | 1.013 (1.001–1.025) | 0.029                |                      |                      |
| Left ventricular mass index                | 1.011 (1.004–1.018) | 0.003                |                      |                      |
| Left ventricular ejection fraction         | 0.954 (0.938–0.971) | <0.001                | 0.970 (0.951–0.990) | 0.004                |
| Gensini score                              | 1.011 (1.006–1.016) | <0.001                |                      |                      |
| KAMIR risk score                           | 2.213 (1.977–2.478) | <0.001                | 1.547 (1.268–1.887) | <0.001                |
| GRACE risk score                           | 1.039 (1.032–1.045) | 0.001                | 1.015 (1.005–1.025) | 0.003                |

Table 4: Cox proportional hazard regression analyses for MACE

| Items                                      | Univariate analysis | Multivariate analysis |
|--------------------------------------------|---------------------|-----------------------|
|                                            | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| Age                                        | 1.045 (1.034–1.057) | <0.001                | 1.027 (1.015–1.040) | <0.001                |
| Female gender                              | 1.737 (1.300–2.320) | <0.001                | 1.370 (1.023–1.836) | 0.035                |
| Heart rate                                 | 1.019 (1.012–1.025) | <0.001                | 1.012 (1.003–1.021) | 0.020                |
| Hypertension                               | 1.318 (1.041–1.668) | 0.022                | 1.136 (1.104–1.168) | 0.006                |
| Killip classification                      | 1.798 (1.589–2.034) | <0.001                | 1.450 (1.258–1.672) | <0.001                |
| Blood glucose                              | 1.037 (1.011–1.063) | 0.004                |                      |                      |
| Uric acid                                  | 1.006 (1.001–1.011) | <0.001                |                      |                      |
| Homocysteine                               | 1.022 (1.018–1.026) | <0.001                | 1.019 (1.015–1.024) | <0.001                |
| Hypersensitive C-reactive protein          | 1.015 (1.007–1.023) | <0.001                | 1.012 (1.003–1.021) | 0.020                |
| N-terminal pro-B-type natriuretic peptide  | 1.179 (1.124–1.234) | <0.001                | 1.136 (1.104–1.168) | 0.006                |
| Left ventricular end-diastolic dimension index | 1.643 (1.259–2.146) | 0.001                |                      |                      |
| Left ventricular end-diastolic volume index | 1.011 (1.003–1.019) | 0.005                |                      |                      |
| Left ventricular mass index                | 1.009 (1.004–1.014) | <0.001                |                      |                      |
| Left ventricular ejection fraction         | 0.976 (0.966–0.986) | <0.001                | 0.982 (0.971–0.993) | 0.001                |
| Wall motion score index                    | 1.782 (1.023–3.105) | 0.041                |                      |                      |
| Gensini score                              | 1.009 (1.006–1.011) | <0.001                |                      |                      |
| GRACE risk score                           | 1.012 (1.009–1.015) | <0.001                | 1.010 (1.007–1.012) | <0.001                |
| KAMIR risk score                           | 1.788 (1.647–1.941) | <0.001                | 1.566 (1.421–1.726) | <0.001                |

CI: confidence interval; GRACE risk score: the Global Registry of Acute Coronary Events risk score; HR: hazard ratio; KAMIR risk score: the Korea Acute Myocardial Infarction Registry risk score; MACE: major adverse cardiovascular events.
14.70 μmol/L; Tertile 2: 14.70–24.50 μmol/L; Tertile 3: >24.50 μmol/L), hs-CRP (Tertile 1: <5.00 mg/L; Tertile 2: 5.00–17.40 mg/L; Tertile 3: >17.40 mg/L), and NT-pro BNP (Tertile 1: <488.20 pg/mL; Tertile 2: 488.20–1254.37 pg/mL; Tertile 3: >1254.37 pg/mL). The cumulative incidences of all-cause death and MACE in these groups of patients are illustrated by the Kaplan-Meier survival curves in Figure 3. The curves revealed significantly worse clinical outcomes with the increase of homocysteine, hs-CRP, or NT-pro BNP level. Log-rank test on the curves identified remarkable differences among these groups in all-cause death (homocysteine: Chi-square = 94.974, P < 0.001; hs-CRP: Chi-square = 13.229, P = 0.001; NT-pro BNP: Chi-square = 89.695, P < 0.001) and MACE (homocysteine: Chi-square = 88.604, P < 0.001; hs-CRP: Chi-square = 8.302, P = 0.016; NT-pro BNP: Chi-square = 97.027, P < 0.001).

**Association of the biomarkers with the KAMIR risk score**

The associations of homocysteine, hs-CRP, and NT-pro BNP with the KAMIR risk score were analyzed by Spearman rank correlation respectively. The results showed that all the 3 biomarkers were significantly and...
positively correlated with the KAMIR score (homocysteine: $r = 0.135$, $P < 0.001$; hs-CRP: $r = 0.149$, $P < 0.001$; and NT-pro BNP: $r = 0.362$, $P < 0.001$).

Combination of the KAMIR risk score with the biomarkers

ROC analysis was performed to assess whether combination of the KAMIR risk score with homocysteine, hs-CRP, or NT-pro BNP could better predict the adverse clinical outcomes. As shown in Figure 4, the AUC increased significantly when the KAMIR score was coupled with homocysteine (all-cause death: AUC = 0.802 vs. 0.890, 95% CI = 0.059–0.012, $Z = 5.982$, $P < 0.001$; MACE: AUC = 0.683 vs. 0.771, 95% CI = 0.062–0.113, $Z = 6.818$, $P < 0.001$), hs-CRP (all-cause death: AUC = 0.802 vs. 0.873, 95% CI = 0.012–0.039, $Z = 3.721$, $P < 0.001$; MACE: AUC = 0.683 vs. 0.712, 95% CI = 0.651–0.730, $Z = 2.022$, $P = 0.031$), or NT-pro BNP (all-cause death: AUC = 0.802 vs. 0.871, 95% CI = 0.0002–0.002, $Z = 2.187$, $P = 0.047$; MACE: AUC = 0.683 vs. 0.720, 95% CI = 0.077–0.103, $Z = 2.974$, $P = 0.003$). Moreover, the AUC increased even more significantly when all the 3 biomarkers were included in the KAMIR score (all-cause death: AUC = 0.802 vs. 0.940, 95% CI = 0.066–0.128, $Z = 6.177$, $P < 0.001$; MACE: AUC = 0.683 vs. 0.789, 95% CI = 0.071–0.127, $Z = 6.900$, $P < 0.001$).

Discussion

In the present study, we compared the predictive ability of the KAMIR risk scoring system and the GRACE risk scoring system in 1093 Chinese patients with STEMI. Our data showed that the KAMIR score is more effective in predicting the clinical outcomes in this cohort of patients. We then evaluated the relationships of the KAMIR score and 3 biomarkers – homocysteine, hs-CRP, and NT-pro BNP. Our hypothesis was that the predictive power of the KAMIR risk score in STEMI could be enhanced by the addition of these biomarkers. This hypothesis was verified by our results. Homocysteine, hs-CRP, and NT-pro BNP were found to be able to serve as independent predictors for cardiovascular events in STEMI, proved by our findings that the increased level of any of them was significantly associated with increased risks of all-cause death and MACE in the patients. The calibration and discriminatory capacity of the KAMIR risk scoring were improved significantly when these biomarkers were also considered. Our data suggest that measurement of homocysteine, hs-CRP, and NT-pro BNP on admission reinforces the predictive power of the KAMIR score for long-term adverse cardiovascular events in Chinese patients with STEMI.

Risk stratification is an important and integral part of the management of patients following STEMI. The GRACE score is an oft-recommended tool for clinical risk stratification in ACS.[12,13] However, this score is developed for short-term prognosis, but vital in STEMI patients is long-term prognosis prediction.[14,15] The composite endpoint evaluated by the GRACE score limits to death and MI, while other cardiovascular events, such as heart failure, angina symptoms, and stroke, also indicate adverse clinical out-
Figure 4: ROC curve analysis. The addition into the KAMIR score with homocysteine (1), hs-CRP (2), and NT-pro BNP (3) and a combination of the three (4). The addition of homocysteine, hs-CRP, and NT-pro BNP improved the predictive power of the KAMIR risk scoring system for all-cause death (A) and MACE (B). KAMIR: the Korea Acute Myocardial Infarction Registry risk score; ROC: receiver-operating characteristic.
comes and are used in clinical researches extensively. Moreover, calculation of the GRACE score is complex. The variables included in the score are age, heart rate, systolic blood pressure, creatinine level, history of congestive heart failure, in-hospital PCI, in-hospital coronary artery bypass graft surgery, previous MI, ST-segment depression, and elevated cardiac markers. It is very difficult to obtain estimates of the cumulative risks of adverse cardiovascular events if without special Web-based calculator or software. Furthermore, existing research on the GRACE scoring recruited predominantly Western patients. It is not clear if this risk prediction model performs as well in Chinese patients. Recently, a novel risk scoring system, the KAMIR score, has been developed in an Asian country, Korea. The model is reported to be simple in calculation and accurate in risk stratification and prediction for long-term prognosis of AMI.[9] Some studies have suggested a greater risk predictive power of the KAMIR score as compared to the GRACE score.[9] This is proved by our observation that the KAMIR score demonstrated a better risk stratification and predictive ability than the GRACE score for long-term clinical outcomes in our STEMI patient population (all-cause death: AUC=0.802 vs. 0.721, P < 0.001; MACE: AUC=0.683 vs. 0.656, P < 0.001). Our study, together with the aforementioned studies, suggests that the KAMIR risk scoring system may be more suitable for patients in Asian countries.

Previous studies have shown that biomarkers, particularly homocysteine,[25] hs-CRP,[19] and NT-pro BNP,[26] are significantly associated with adverse cardiovascular events in AMI. Homocysteine can induce endothelial dysfunction, vascular smooth muscle proliferation, cholesterol and triglyceride metabolism dysregulation, inflammatory activation, collagen synthesis and arterial wall elastic deterioration, and thrombus formation.[27-29] Therefore, homocysteine plays an important role in the pathogenesis of atherosclerosis and coagulation.[30,31] Recently, hyperhomocysteine is identified as an intensive and independent risk factor for atherosclerotic diseases.[32] Prospective research has demonstrated that hyperhomocysteine can predict cardiovascular events in coronary artery disease.[133] Hs-CRP, which is synthesized by liver, is a non-specific marker of systemic inflammatory response in acute period. Elevated plasma hs-CRP level is considered as linked to inflammation, thrombosis, decrease in nitric oxide synthesis, expression of adhesion molecules, and inhibition of the physiologic fibrinolysis.[34,35] Due to its important role in the immune response, hs-CRP is implicated in the development and complications of atherosclerosis.[19] Clinical research has illuminated that hs-CRP is a strong predictor of clinical events in patients with AMI.[16] NT-pro BNP is a neurohormone synthesized predominantly in ventricular myocardium, which reveals cardiac neurohormonal activation after myocardial damage.[20] As an important indicator of heart function, NT-pro BNP can reflect the systolic and diastolic function of the left and right ventricle,[37] and can reflect the degree of myocardial injury.[38] The association of plasma NT-pro BNP level with mortality in AMI patients has been confirmed.[24]

The biomarkers discussed above reveal the pathological process of STEMI from multiple dimensions including metabolism, inflammation, and neuroendocrine. However, they are not involved in the KAMIR scoring system. The comparison of the baseline data between patients with and without MACE in this study showed that the levels of homocysteine, hs-CRP, and NT-pro BNP were significantly higher in patients who experienced such events. Both univariate and multivariate Cox proportional hazard regression analysis revealed that homocysteine, hs-CRP, and NT-pro BNP were independent risk factors and strong predictors for adverse cardiovascular events. Kaplan-Meier survival curves also verified that the probability of all-cause death and MACE significantly rose with the increase of homocysteine, hs-CRP, or NT-pro BNP level. Moreover, these biomarkers were found positively correlated with the KAMIR risk score, which means that the predictive power of the KAMIR score could be enhanced when combined with either homocysteine (AUC: 0.802 to 0.890 for all-cause death, 0.683 to 0.771 for MACE), hs-CRP (AUC: 0.802 to 0.873 for all-cause death, 0.683 to 0.712 for MACE), NT-pro BNP (AUC: 0.802 to 0.871 for all-cause death, AUC=0.683 to 0.720 for MACE), or all of them (AUC: 0.802 to 0.940 for all-cause death, AUC: 0.683 to 0.789 for MACE) for long-term clinical outcomes in patients with STEMI.

**Study limitations**

The patients included in this study were from only two hospitals. Our findings need to be further proved by large multicenter research. Since our study is based exclusively on Chinese patients, the results should be applied cautiously to other ethnic populations.

**Conclusions**

In conclusion, our study confirms that the KAMIR score performs better than the GRACE score in risk stratification and prediction for adverse prognosis in Chinese STEMI patients. The biomarkers, including homocysteine, hs-CRP, and NT-pro BNP, can independently predict adverse cardiovascular events in STEMI. Using these biomarkers in combination with the KAMIR system derives a more robust predictive power for long-term clinical outcomes in patients with STEMI.

**Acknowledgements**

None.

**Funding**

None.

**Conflict of interest**

The authors have no other funding, financial relationships, or conflicts of interest to disclose.

**References**

1. Qiu JP, Zhang Q, Lu JD, Wang HR, Lin J. Ge ZR, et al. Direct ambulance transport to catheterization laboratory reduces door-to-balloon time in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the DIRECT-STEMI study. Chin Med J 2011;124:805–810. doi: 10.3760/cma.j.issn.0366-6999.2011.06.002.
2. O’Gara PT, Kushner FG, Ascheim DD, Tommaso CL. American College of Emergency P, Society for Cardiovascular A, Interventions. 2013 ACC/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideline. J Am Coll Cardiol 2013;61:e78–e140. doi: 10.1016/j.jacc.2013.03.001.

3. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. Task Force on the management of ST-segment elevation myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2013;34:2564–2623. doi: 10.1093/eurheartj/ect215.

4. Zhao FH, Chen YD, Song XT, Pan WQ, Jin ZN, Yuan F, et al. Predictive factors of recurrent angina after acute coronary syndrome: the global registry acute coronary events from China (Sino-GRACE). Eur Heart J 2013;34:339–348. doi: 10.1093/eurheartj/eht121.

5. Yan AT, Yan RT, Tan M, Casanova A, Labinaz M, Sridhar K, et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J 2007;28:1072–1078. doi: 10.1093/eurheartj/ehm123.

6. Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (PROspective Study of普卡clinically relevant Events in Acute Myocardial Infarction, PROTECTAMI). BMJ 2006;333:1091. doi: 10.1136/bmj.38985.64681.55.

7. Roe MT, Messenger JC, Weintraub WS, Cannon CP, Fonarow GC, O’Connor CM, et al. C-reactive protein improves risk prediction in patients with non-ST-segment elevation acute coronary syndrome. Eur Heart J 2010;31:290–298. doi: 10.1093/eurheartj/ehq256.

8. Kim HK, Jeong MH, Ahn Y, Kim JH, Chae SC, Kim YJ, et al. A new risk score system for the assessment of clinical outcomes in patients with non-ST-segment elevation myocardial infarction. J Int J Cardiol 2010;145:450–454. doi: 10.1016/j.ijcard.2009.06.001.

9. Kim HK, Jeong MH, Ahn Y, Kim JH, Chae SC, Kim YJ, et al. Hospital discharge risk score system for the assessment of clinical outcomes in patients with acute myocardial infarction (Korea Acute Myocardial Infarction Registry (KAMIR) score). J Am Coll Cardiol 2011;107:965–971. doi: 10.1016/j.jacc.2010.11.018.

10. Fan Y, Wang J, Zhang S, Wan Z, Zhou D, Ding Y, et al. Homocysteine enhances the predictive value of the GRACE risk score in patients with ST-elevation myocardial infarction. Anaol J Cardiol 2017;18:182–193. doi: 10.14744/AnatolCardiol.2017.7798.

11. Zhang S, Wan Z, Zhang Y, Fan Y, Gu W, Li F, et al. Neutrophil count improves the GRACE risk score prediction of clinical outcomes in patients with ST-elevation myocardial infarction. Anaol J Cardiol 2015;241:723–728. doi: 10.1016/theroscleros.2015.06.035.

12. Fan ZF, Zhou D, Xue JH, Wu Y, Wang H, Zhao Y, et al. Combination of mean platelet volume and the GRACE risk score better predicts future cardiovascular events in patients with acute coronary syndrome. Platelets 2014;25:447–451. doi: 10.1093/platelets/ftp095.

13. Manzano-Fernandez S, Lopez-Cuenca A, Januzzi JL, Parra-Pallares S, Mateo-Martinez A, Sanchez-Martinez M, et al. Usefulness of beta-trace protein and cystatin C for the management of mortality in non ST-segment elevation acute coronary syndromes. Am J Cardiol 2012;110:1240–1248. doi: 10.1016/j.amjcard.2012.06.027.

14. Schiele F, Meneveau N, Seronde MF, Chopard R, Descotes-Genon V, Duthel J, et al. C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J 2010;31:290–297. doi: 10.1093/eurheartj/ehp273.

15. Khan SQ, Narayan H, Nj KH, Dhillon OS, Kelly D, Quinn P, et al. N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndrome. Clin Sci 2009;117:31–39. doi: 10.1042/CS20080419.

16. Widera C, Pencina MJ, Messner A, Kempf T, Benthann K, Marquardt L, et al. Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome. Eur Heart J 2012;33:1095–1104. doi: 10.1093/eurheartj/ehq444.

17. Harris WS, Kennedy KF, O’Keefe JH Jr, Spertus JA. Red blood cell fatty acid levels improve GRACE score prediction of 2-year mortality in patients with myocardial infarction. Int J Cardiol 2013;168:53–59. doi: 10.1016/j.ijcard.2012.09.076.

18. Reserterol L, Paus B, Bohn M, Bakken A, Eriksson J, Malinow MB, et al. Plasma total homocysteine levels and prognosis in patients with previous premature myocardial infarction: a 10-year follow-up study. J Intern Med 2003;253:284–292. doi: 10.1046/j.1365-2796.2003.01096.x.
36. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000;343:1139–1147. doi: 10.1056/NEJM200010193431602.

37. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiol Pol 2016;74:1037–1147. doi: 10.5603/KP.2016.0141.

How to cite this article: Wang JJ, Fan Y, Zhu Y, Zhang JD, Zhang SM, Wan ZF, Su HL, Jiang N. Biomarkers enhance the long-term predictive ability of the KAMIR risk score in Chinese patients with ST-elevation myocardial infarction. Chin Med J 2019;132:30–41. doi: 10.1097/CM9.0000000000000015